Optinose (NASDAQ: OPTN) has announced preliminary unaudited net product revenue of $22.4 million for the fourth quarter of ...

YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced ...

"Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth ...

(RTTNews) - Optinose, Inc. (OPTN), a pharmaceutical company focused on ear, nose and throat or ENT and allergy, announced Wednesday preliminary XHANCE (fluticasone propionate) net product revenue ...

Optinose reports preliminary fourth quarter 2024 XHANCE revenue of $22.4 million, indicating sustained prescription growth. Full results expected in March. Optinose, a pharmaceutical company ...

In light of these financial results, OptiNose revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite this adjustment, the company ...

(MENAFN- GlobeNewsWire - Nasdaq) Preliminary XHANCE prescription growth rate from third quarter to fourth quarter 2024 estimated to be approximately 20% YARDLEY, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE ...

In light of these financial results, OptiNose revised its 2024 sales forecast for Xhance, its nasal spray treatment, to a range of $75 million to $79 million. Despite this adjustment, the company ...

“Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth ...